FAST FACTS
FOUNDER(S):
Robert S. Capon
Dr. Joel Linden
Dr. Timothy MacDonald
INNOVATION(S):
Biotechnology/Pharmaceuticals
Cancer Therapies/Tests
HEADQUARTERS:
Charlottesville, VA
FOUNDED:
1999
TSC MEMBER INSTITUTION(S):
University of Virginia
FUNDING AGENCY(S):
National Institutes of Health
US Department of Agriculture
STATUS:
Acquired
ACQUIRING COMPANY:
Clinical Data
|
ADENOSINE THERAPEUTICS, LLC
ABOUT THE COMPANY:
Supported by research grants from the National Institutes of Health and the US Department of Agriculture, the University of Virginia has led research into adenosine, a molecule found in all cells. The body uses adenosine to signal inflammation and tissue injury. Understanding this compound has the potential to unleash therapies to treat heart disease, diabetes, arthritis, cancer and atherosclerosis.
Joel Linden, University of Virginia professor of cardiovascular medicine and Timothy Macdonald, University of Virginia professor of chemistry recognized the power of this research. They collaborated with business leader Robert Capon to establish a startup company based around University of Virginia patents in this area. The company, Adenosine Therapeutics, was acquired in 2008 by Clinical Data, a global pharmaceutical company.
UNIVERSITY-BASED RESEARCH CONNECTION:
Since its founding in 1999 by Joel Linden, University of Virginia professor
of cardiovascular medicine and Timothy MacDonald, University of Virginia professor of chemistry, Adenosine Therapeutics has maintained its ties to the University of Virginia and its support of university-based research. In collaboration with many different researchers, the company participated in a large number of Small Business Innovation Research grants, thereby enabling basic and translational research with federal funding. This research has resulted in over 20 patents held by University of Virginia and nearly $3 million in sponsored research by the company. In addition, tens of millions of dollars of University of Virginia basic research grants have been won using Adenosine Therapeutics compounds, and over 100 scientific papers have been published on the pharmacology and physiology of adenosine. The company has given over one million dollars to the University of Virginia Patent Foundation, employed numerous University of Virginia students, and has also participated in business school cases at the Darden Business School.
ROLE OF FEDERAL RESEARCH FUNDING:
Research uncovering adenosine’s role in cell signaling and the development of specialized molecules has been supported by grants from the National Institutes of Health and the US Department of Agriculture.
 Read The Full Report Here
|
Printer-Friendly Version
ADENOSINE THERAPEUTICS, LLC